Ligand Pharmaceuticals (United Kingdom)
Our diversified portfolio of royalty assets generates consistent and predictable revenue streams for our shareholders. It includes treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten lifespan and quality of life for billions of people. We also maintain and license our Captisol® and NITRICIL™ technology platforms with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest ph
Basic Information
- Category: business
- Website: https://www.ligand.com/
Documented Facts
- Inception (Wikidata): 1987 (Source 2: Wikidata Q61931085, revision 2474150826)
- Country (Wikidata; date unspecified): United Kingdom (Source 2: Wikidata Q61931085, revision 2474150826; Source 3: Wikidata label: Q145, revision 2554939741)
- Official website (Wikidata; date unspecified): https://www.ligand.com/ (Source 2: Wikidata Q61931085, revision 2474150826)
Evidence and Sources
- Ligand Pharmaceuticals (United Kingdom) — Official Website (official)
- Wikidata Q61931085, revision 2474150826 (knowledge-base)
- Wikidata label: Q145, revision 2554939741 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Ligand Pharmaceuticals (United Kingdom).
- Canonical profile: https://brandsource.ai/brands/ligand-pharmaceuticals-united-kingdom
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/ligand-pharmaceuticals-united-kingdom/json-ld
- Citation profile API: https://brandsource.ai/api/brands/ligand-pharmaceuticals-united-kingdom/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Our diversified portfolio of royalty assets generates consistent and predictable revenue streams for our shareholders. It includes treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten lifespan and quality of life for billions of people. We also maintain and license our Captisol® and NITRICIL™ technology platforms with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest ph
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.